von Willebrand factor–cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke
Open Access
- 8 October 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 114 (15), 3329-3334
- https://doi.org/10.1182/blood-2009-03-213264
Abstract
Stroke is a leading cause of death and disability. The only therapy available is recombinant tissue plasminogen activator, but side effects limit its use. Platelets play a crucial role during stroke, and the inflammatory reaction promotes neurodegeneration. von Willebrand factor (VWF), an adhesion molecule for platelets, is elevated in patients with acute stroke. The activity of VWF is modulated by ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats-13) that cleaves VWF to smaller less-active forms. We recently documented that ADAMTS13 negatively regulates both thrombosis and inflammation. We report that deficiency or reduction of VWF reduces infarct volume up to 2-fold after focal cerebral ischemia in mice, thus showing the importance of VWF in stroke injury. In contrast, ADAMTS13 deficiency results in larger infarctions, but only in mice that have VWF. Importantly, infusion of a high dose of recombinant human ADAMTS13 into a wild-type mouse immediately before reperfusion reduces infarct volume and improves functional outcome without producing cerebral hemorrhage. Furthermore, recombinant ADAMTS13 did not enhance bleeding in a hemorrhagic stroke model. Our findings show the importance of VWF in regulating infarction and suggest that recombinant ADAMTS13 could be considered as a new therapeutic agent for prevention and/or treatment of stroke.Keywords
This publication has 34 references indexed in Scilit:
- Deficiency of von Willebrand factor protects mice from ischemic strokeBlood, 2009
- ADAMTS13: a new link between thrombosis and inflammationThe Journal of Experimental Medicine, 2008
- Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraBlood, 2008
- Inflammation induces hemorrhage in thrombocytopeniaPublished by American Society of Hematology ,2008
- The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosisBlood, 2008
- ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpuraEuropean Journal of Pediatrics, 2006
- High von Willebrand Factor Levels Increase the Risk of First Ischemic StrokeStroke, 2006
- Systemic antithrombotic effects of ADAMTS13The Journal of Experimental Medicine, 2006
- Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.JCI Insight, 1998
- Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcomePlatelets, 1998